Raptiva falloff weighs on Merck KGaA

Hit by a decline in demand for the psoriasis drug Raptiva--recently linked to the deaths of two patients who developed the rare brain infection PML (progressive multifocal leukoencephalopathy)--Merck KGaA posted a fourth-quarter loss of 279.5 million euros ($374 million). Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.